Israel’s Teva Pharmaceuticals received approval from the Food and Drug Administration for the SIMLANDI (adalimumab-ryvk) injection, for the treatment of a number of different forms of arthritis, colitis and Chron’s Disease, among others. The drug is developed together with Iceland’s Alvotech and its marketing could lead to billions in sales. SIMLANDI is the first high-concentration, […]